The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes
Abstract
Chemotherapy dose intensity represents unit dose of chemotherapy administered per unit time. Dose intensity can be increased or decreased through altering dose administered, time interval of administration, or both. Evidence supporting the importance of delivered chemotherapy dose intensity on clinical outcomes in patients with potentially curable malignancies comes from in vitro studies of cancer cell lines and abundant in vivo preclinical studies, in addition to retrospective and prospective clinical trials in both advanced and early-stage disease settings. Myelosuppression continues to represent the major dose-limiting toxicity of cancer chemotherapy, resulting in considerable morbidity and mortality along with frequent reductions in chemotherapy dose intensity, which may compromise disease control and survival. Several retrospective and prospective randomized trials have shown that reductions in the chemotherapy dose intensity established in efficacy studies may compromise long-term disease control and survival. Despite compelling data, surveys in the United States and elsewhere have reported that dose reductions and delays frequently occur in clinical practice, even in the potentially curative setting. Alternatively, an increase in dose intensity above standard may be achieved through either increasing the dose of individual agents (dose escalation) or compressing or shortening the treatment interval (dose-dense). In early studies, dose-dense schedules showed an increase in survival, whereas the benefit of dose escalation studies has been less consistent and may be accompanied by other dose-limiting toxicities. This article focuses on the rationale for delivering full chemotherapy dose intensity, the apparent reasons for failing to deliver treatment, and available strategies for sustaining full chemotherapy dose intensity when indicated. The delivery of full chemotherapy dose intensity in patients with potentially curable malignancies should be considered a quality of care indicator in clinical oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BODEY, G. P., BUCKLEY, M., SATHE, Y. S., & FREIREICH, E. J. (1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-2-328 · Cited by 2,469
Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Self-citationCitron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
Kuderer, N. M., Dale, D. C., Crawford, J., Cosler, L. E., & Lyman, G. H. (2006) · Cancer · doi:10.1002/cncr.21847 · Cited by 1,176
Self-citationBonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., & Brambilla, C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321401 · Cited by 1,049
The importance of dose intensity in chemotherapy of metastatic breast cancer.
Hryniuk, W., & Bush, H. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.11.1281 · Cited by 885
Kuderer, N. M., Dale, D. C., Crawford, J., & Lyman, G. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8823 · Cited by 720
Self-citationDose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer
Budman, D. R., Berry, D. A., Cirrincione, C. T., Henderson, Wood, W. C., Weiss, R. B., Ferree, C. R., Muss, H. B., Green, M. R., Norton, L., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.16.1205 · Cited by 577
Aapro, M. S., Cameron, D. A., Pettengell, R., Bohlius, J., Crawford, J., Ellis, M., Kearney, N., Lyman, G. H., Tjan-Heijnen, V. C., Walewski, J., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.002 · Cited by 539
Self-citationLyman, G. H., Dale, D. C., & Crawford, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.002 · Cited by 464
Self-citationTumor size, sensitivity to therapy, and design of treatment schedules.
Norton, L., & Simon, R. M. (1977) · PubMed · Cited by 447
Kwak, L. W., Halpern, J., Olshen, R. A., & Horning, S. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.6.963 · Cited by 431
Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases
Hruban, R. H., Shiu, M. H., Senie, R. T., & Woodruff, J. M. (1990) · Cancer · doi:10.1002/1097-0142(19900915)66:6<1124::aid-cncr2820660608>3.0.co;2-t · Cited by 364
Hassett, M. J., O'Malley, A. J., Pakes, J. R., Newhouse, J. P., & Earle, C. C. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj305 · Cited by 360
Risk Models for Predicting Chemotherapy-Induced Neutropenia
Lyman, G. H., Lyman, C. H., Agboola, O., & Anc Study Group (2005) · The Oncologist · doi:10.1634/theoncologist.10-6-427 · Cited by 336
Self-citationBody Mass Index and Outcomes in Patients Who Receive Adjuvant Chemotherapy for Colon Cancer
Dignam, J. J., Polite, B. N., Yothers, G., Raich, P., Colangelo, L., O'Connell, M. J., & Wolmark, N. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj442 · Cited by 325
Lyman, G. H., Dale, D. C., Friedberg, J., Crawford, J., & Fisher, R. I. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.213 · Cited by 315
Self-citationMalin, J. L., Schneider, E. C., Epstein, A. M., Adams, J., Emanuel, E. J., & Kahn, K. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3365 · Cited by 293
Undertreatment of Obese Women Receiving Breast Cancer Chemotherapy
Griggs, J. J., Sorbero, M. E. S., & Lyman, G. H. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.11.1267 · Cited by 289
Self-citationBonneterre, J. M., Roche, H. H., Kerbrat, P., Bremond, A. G., Fumoleau, P., Namer, M., Goudier, M.-J., Schraub, S., Fargeot, P., & Chapelle-Marcillac, I. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.059 · Cited by 276
Meyerhardt, J. A., Niedzwiecki, D., Hollis, D., Saltz, L. B., Mayer, R. J., Nelson, H., Whittom, R., Hantel, A., Thomas, J., & Fuchs, C. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6687 · Cited by 259
Kinetics of mammary tumor cell growth and implications for therapy
Skipper, H. E. (1971) · Cancer · doi:10.1002/1097-0142(197112)28:6<1479::aid-cncr2820280622>3.0.co;2-m · Cited by 234
Di Maio, M., Gridelli, C., Gallo, C., Shepherd, F., Piantedosi, F. V., Cigolari, S., Manzione, L., Illiano, A., Barbera, S., Robbiati, S. F., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70255-2 · Cited by 234
Lyman, G. H., Morrison, V. A., Dale, D. C., Crawford, J., Delgado, D. J., & Fridman, M. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000119262 · Cited by 224
Self-citationLyman, G. H., Kuderer, N. M., & Djulbegovic, B. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01036-7 · Cited by 221
Self-citationRacial Disparity in the Dose and Dose Intensity of Breast Cancer Adjuvant Chemotherapy
Griggs, J. J., Sorbero, M. E. S., Stark, A. T., Heininger, S. E., & Dick, A. W. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1025481505537 · Cited by 185
Rosner, G. L., Hargis, J. B., Hollis, D. R., Budman, D. R., Weiss, R. B., Henderson, I. C., & Schilsky, R. L. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.11.3000 · Cited by 178
The calculation of actual or received dose intensity: a comparison of published methods.
Longo, D. L., Duffey, P. L., DeVita, V. T., Wesley, M. N., Hubbard, S. M., & Young, R. C. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.11.2042 · Cited by 177
Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese
Sparreboom, A., Wolff, A. C., Mathijssen, R. H. J., Chatelut, E., Rowinsky, E. K., Verweij, J., & Baker, S. D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.2938 · Cited by 168
Doorduijn, J. K., van der Holt, B., van Imhoff, G. W., van der Hem, K. G., Kramer, M. H. H., van Oers, M. H. J., Ossenkoppele, G. J., Schaafsma, M. R., Verdonck, L. F., Verhoef, G. E. G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.076 · Cited by 168
Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women
Hershman, D. L., Wang, X., McBride, R. B., Jacobson, J. S., Grann, V. R., & Neugut, A. I. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9206-z · Cited by 157
Social and Racial Differences in Selection of Breast Cancer Adjuvant Chemotherapy Regimens
Griggs, J. J., Culakova, E., Sorbero, M. E. S., Poniewierski, M. S., Wolff, D. A., Crawford, J., Dale, D. C., & Lyman, G. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2749 · Cited by 149
Self-citationDose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy
Shayne, M., Culakova, E., Poniewierski, M. S., Wolff, D. A., Dale, D. C., Crawford, J., & Lyman, G. H. (2007) · Cancer · doi:10.1002/cncr.22939 · Cited by 145
Self-citationShayne, M., Crawford, J., Dale, D. C., Culakova, E., Lyman, G. H., & for the ANC Study Group (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9254-4 · Cited by 145
Self-citationGriggs, J. J., Culakova, E., Sorbero, M. E. S., van Ryn, M., Poniewierski, M. S., Wolff, D. A., Crawford, J., Dale, D. C., & Lyman, G. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3063 · Cited by 135
Self-citationMayers, C., Panzarella, T., & Tannock, I. F. (2001) · Cancer · doi:10.1002/1097-0142(20010615)91:12<2246::aid-cncr1255>3.0.co;2-4 · Cited by 132
Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index
Colleoni, M. A., Li, S., Gelber, R. D., Price, K. N., Coates, A. S., Castiglione‐Gertsch, M., & Goldhirsch, A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67110-3 · Cited by 129
Field, K. M., Kosmider, S., Jefford, M., Michael, M., Jennens, R. R., Green, M., & Gibbs, P. (2008) · Journal of Oncology Practice · doi:10.1200/jop.0832001 · Cited by 97
Ardizzoni, A., Favaretto, A. G., Boni, L., Baldini, E., Castiglioni, F., Antonelli, P., Pari, F., Tibaldi, C., Altieri, A. M., Barbera, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.140 · Cited by 88
Are medical oncologists biased in their treatment of the large woman with breast cancer?
Madarnas, Y., Sawka, C. A., Franssen, E., & Bjarnason, G. A. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010635328299 · Cited by 65
Chemotherapy dose intensity and quality cancer care.
Lyman, G. H. (2006) · PubMed · Cited by 61
Self-citationPrinciples of Medical Oncology
Hait, W. N., Holland, J. F., Frei, E., Kufe, D. W., Bast, R. C., & Hong, W. K. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm046 · Cited by 50
Balducci, L., Hardy, C. L., & Lyman, G. H. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-387-23962-6_6 · Cited by 48
Self-citationBreast cancer adjuvant chemotherapy dosing in obese patients
Greenman, C., Jagielski, C. H., & Griggs, J. J. (2008) · Cancer · doi:10.1002/cncr.23416 · Cited by 43
The quality of chemotherapy and its quality assurance
Ottevanger, P. B., & Mulder, P. H. M. D. (2005) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2005.02.019 · Cited by 13
Time is Money for Both the Healthy and the Sick
Lyman, G. H. (2005) · Medical Care · doi:10.1097/01.mlr.0000168840.24299.29 · Cited by 9
Self-citation
Cited by
Adipocyte and lipid metabolism in cancer drug resistance
Cao, Y. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127201 · Cited by 522
Griggs, J. J., Mangu, P. B., Anderson, H., Balaban, E. P., Dignam, J. J., Hryniuk, W. M., Morrison, V. A., Pini, T. M., Runowicz, C. D., Rosner, G. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9436 · Cited by 485
Self-citationLyman, G. H., Abella, E., & Pettengell, R. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.12.006 · Cited by 348
Self-citationKleckner, I. R., Kamen, C., Gewandter, J. S., Mohile, N. A., Heckler, C. E., Culakova, E., Fung, C., Janelsins, M. C., Asare, M., Lin, P.-J., et al. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-017-4013-0 · Cited by 309
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M., & de Vries, E. G. E. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0708 · Cited by 254
Metadata
- Authors
- Lyman, G. H.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2009-01
- Volume
- 7
- Issue
- 1
- Pages
- 99-108
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W1804059878
- Cited by
- 383
- References
- 49
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.